Castle biosciences stock.

Castle Biosciences Stock Down 0.1 %. NASDAQ:CSTL opened at $19.97 on Monday. Castle Biosciences, Inc. has a 52 week low of $9.26 and a 52 week high of $29.59. The company’s 50 day moving average ...

Castle biosciences stock. Things To Know About Castle biosciences stock.

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September ...Jean Carruthers Faculty Owner/Co-Owner Founder/Co-Founder: Carruthers Instruments; Consulting Fee: Alastin Skincare, Allergan Aesthetics, Appiell, Avari, Evolus ...Jun 2, 2023 · Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ... Revenue growth over the past 12 months for CASTLE BIOSCIENCES INC comes in at 55.17%, a number that bests 91.18% of the US stocks we're tracking. Stocks with similar financial metrics, market capitalization, and price volatility to CASTLE BIOSCIENCES INC are SILK, ONTF, IGC, FLGT, and BMRA. Visit CSTL's SEC page to see the company's …Which Castle Biosciences insiders have been selling company stock? The following insiders have sold CSTL shares in the last 24 months: Daniel Bradbury ($6,274,776.69), and Derek J Maetzold ($1,265,588.97).

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago.Jul 13, 2023 · Shares of Castle Biosciences ( CSTL -7.22%) were down more than 20.2% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare stock closed ...

The bid-ask spread can indicate a stock’s liquidity, which is how easy it is to buy and sell in the marketplace. Often, a smaller spread suggests higher liquidity, meaning more buyers …

Castle Biosciences-stock Castle Biosciences Inc Registered Shs Stock , CSTL 19.78 + +% After-market 04:20:00 PM NAS Add to watchlist 19.78 -0.10 -0.50% Official Close …On average, Wall Street analysts predict. that Castle Biosciences's share price could reach $32.13 by Aug 4, 2024. The average Castle Biosciences stock price prediction forecasts a potential upside of 63.57% from the current CSTL share price of $19.64.Nov 30, 2023 · A high-level overview of Castle Biosciences, Inc. (CSTL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. David Kabakoff CSTL stock SEC Form 4 insiders trading. David has made over 21 trades of the Castle Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 30,000 units of CSTL stock worth $2,252,100 on 17 June 2021.. The largest trade he's ever made was selling 250,000 units of Castle …

Of the 172 institutional investors that purchased Castle Biosciences stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Granahan Investment Management LLC ($1.82M), Principal Financial Group Inc. ($1.13M), Millennium Management LLC ($1.03M), Wasatch Advisors Inc. …

Shares of Castle Biosciences ( CSTL -7.22%) were down more than 20.2% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare stock closed ...

Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Castle Biosciences, Inc. Stock Symbol NASDAQ:CSTL. Company Type For Profit. Contact Email [email protected]. Phone Number 602-535-1997. Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the …CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 77-0701774 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 820 S. Friendswood Drive, Suite 201, Friendswood, Texas 77546 (Address of principal executive offices) (Zip Code) (866) 788-9007 In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...Castle Biosciences Inc. Watch list Set a price target alert After Hours Last Updated: Nov 3, 2023 5:21 p.m. EDT Delayed quote $ 17.95 -0.03 -0.17% After Hours Volume: 7.02K Advanced Charting... Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes.Shares of Castle Biosciences are trading down 1.98% over the last 24 hours, at $13.40 per share. A move to $30.00 would account for a 123.88% increase from the current share price. About Castle ...Jun. 03, 2022 5:05 PM ET Castle Biosciences, Inc. (CSTL) SA Transcripts. 140.86K Follower s. The following slide deck was published by Castle Biosciences, Inc. in conjunction with this event. View ...

Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-2.84 Market Cap $537.94 M Shares Outstanding 26.91 M Public Float 24.91 M Yield CSTL is not currently paying a regular dividend. Latest Dividend N/A...On November 3, 2023, Castle Biosciences Inc (CSTL) stock is expected to experience positive growth, according to analysts. The 8 analysts offering 12-month price forecasts for CSTL have a median target of $32.50, with a high estimate of $40.00 and a low estimate of $25.00.By providing your email address below, you are providing consent to Castle Biosciences to send you the requested Investor Email Alert updates. * Required. Email Address*. Investor Alert Options*. News. Events & Presentations. Quarterly Reports. Annual Reports. SEC Filings.Apr 5, 2022 · AltheaDx filed for an initial public stock offering in December 2014 but shelved the proposed stock sale in early 2015. Castle Biosciences, which went public in 2019, makes tests that help guide ... The estimated Net Worth of Frank Stokes is at least $2.05 Million dollars as of 4 April 2023. Mr. Stokes owns over 4,000 units of Castle Biosciences stock worth over $556,435 and over the last 3 years he sold CSTL stock worth over $0. In addition, he makes $1,498,230 as Chief Financial Officer at Castle Biosciences.

Miles has made over 2 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,825 units of CSTL stock worth $76,653 on 2 June 2023.

The bid-ask spread can indicate a stock’s liquidity, which is how easy it is to buy and sell in the marketplace. Often, a smaller spread suggests higher liquidity, meaning more buyers …Castle Biosciences Stock Up 9.0 %. CSTL stock opened at $14.23 on Tuesday. The company has a market cap of $381.51 million, a PE ratio of -4.25 and a beta of 0.85. The business has a 50-day simple ...Castle Biosciences Inc Registered Shs's market capitalization is $534.59 M by 26.91 M shares outstanding. Castle Biosciences Stock Snapshot 16.00Castle Biosciences Company Info. Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.47 per share a year ago.Castle Biosciences (NASDAQ:CSTL) has a recorded net income of -$67.14 million. CSTL has generated -$2.84 earnings per share over the last four quarters. What is Castle Biosciences's EPS forecast for next year? Castle Biosciences's earnings are expected to grow from ($3.15) per share to ($3.00) per share in the next year.Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Europe PMC is an archive of life sciences journal literature.Europe PMC is an archive of life sciences journal literature.

The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.

CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 77-0701774 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 820 S. Friendswood Drive, Suite 201, Friendswood, Texas 77546 (Address of principal executive offices) (Zip Code) (866) 788-9007

Castle Biosciences Inc Registered Shs's market capitalization is $534.59 M by 26.91 M shares outstanding. Castle Biosciences Stock Snapshot 16.00Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma.Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...Simply Wall St. June 8, 2023 at 3:34 AM · 3 min read. The Castle Biosciences, Inc. ( NASDAQ:CSTL) share price has fared very poorly over the last month, falling by a substantial 34%. Instead of ...Castle Biosciences Stock Down 0.1 %. NASDAQ:CSTL opened at $19.97 on Monday. Castle Biosciences, Inc. has a 52 week low of $9.26 and a 52 week high of $29.59. The company’s 50 day moving average ...KMO: Director of Operations - Castle Biosciences; Stock Ownership - Castle Biosciences. PJLS: Other Remuneration - Indiana University. SB: Other Remuneration - Indiana University. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. Introduction. Thymomas and thymic …DOI: 10.1200/JOP.2017.022152 Journal of Oncology Practice - published online before print March 28, 2017 . PMID: 28350513

CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 77-0701774 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 820 S. Friendswood Drive, Suite 201, Friendswood, Texas 77546 (Address of principal executive offices) (Zip Code) (866) 788-9007The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ...In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.Instagram:https://instagram. does it cost to transfer insurance to another carqs tickerbiggest wealth management firmsoakmark international All earnings call transcripts on Castle Biosciences, Inc. (CSTL) stock. Read or listen to the conference call. Download the investor presentation - earnings ...-15.00 Russell 2000 +11.96 -1.56 Gold Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.88 +0.03 (+0.15%) At close: 01:00PM EST 19.88 0.00... top small cap etfamazon and doordash Castle Biosciences stock opened at $19.97 on Monday. The firm has a market capitalization of $537.39 million, a P/E ratio of -7.03 and a beta of 0.97. The company has a 50-day simple moving ... etb bogota 4 Wall Street research analysts have issued 1-year price targets for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $41.00. On average, they anticipate the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 64.4% from the stock's current price.Apr 4, 2022 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ...